Hirofumi Jono
Associate professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Year:
2026
Year:
2026
Aim Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady‐state blood concentrations of donepezil, risperidone, and the major metabolites of both drugs in a real‐world clinical setting. Methods A non‐randomized, open‐label, single‐arm study examining drug–drug interactions was conducted. Fifteen dementia patients taking donepezil for at least 4 weeks and eight schizophrenia patients taking risperidone for at least 2 weeks were orally administered 2.5 g of yokukansan three times a day before or between meals, and blood samples were collected before and 8 weeks after starting co‐treatment with yokukansan. Plasma concentrations of donepezil, risperidone, and each metabolite were measured using high‐performance liquid chromatography–tandem mass spectrometry and compared before and after the 8‐week administration of yokukansan. Results The plasma concentrations of donepezil and its metabolites (6‐ O ‐desmethyl‐donepezil, 5‐ O ‐desmethyl‐donepezil, and donepezil‐ N ‐oxide), risperidone, and its metabolite paliperidone did not differ before and after the 8‐week treatment with yokukansan. Conclusions The findings of this study show that the concomitant use of yokukansan may have little clinical impact on the steady‐state blood levels of donepezil and risperidone in patients with dementia or schizophrenia.
Year:
2024
Year:
2022
Collaborators (2)
Norio Yasui‐Furukori
Associate Professor
Dokkyo Medical University
Junji Saruwatari
Professor
Kumamoto University
Make your next move.
Prepare your application
Review drafts before you send them.